Close mobile menu×
Close mobile menu

Neil A. Shneider, MD, PhD

Board Certifications: 
Neurology
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-1319

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Neurology

Clinical Expertise

  • ALS (Amyotrophic Lateral Sclerosis)
  • Neuromuscular Disease
  • Lou Gehrig's Disease

Specialties

Education & Training

  • BA, Harvard College
  • MD, Columbia College of Physicians and Surgeons
  • PhD, Columbia University, NY

Honors & Awards

2012 Stephen Q. Shafer Award for Humanism in Neurology

About Neil Shneider

Dr. Neil Shneider is a physician-scientist with expertise in neuromuscular development and disease. He is a graduate of Harvard College and of the MD-PhD program of the Columbia University College of Physicians and Surgeons, and he was Chief Resident of the Harvard Longwood Neurology Training Program.

Dr. Shneider completed his graduate work in the laboratory of Dr. Richard Axel and his postdoctoral fellowship in the laboratory of Dr. Thomas Jessell. After several years in the Intramural Program of the National Institute of Neurological Disorders and Stroke, Dr. Shneider returned to Columbia University as Assistant Professor of Neurology in the Neuromuscular Division. He is a member of the Center for Motor Neuron Biology and Disease and of the H. Houston Merritt Clinical Research Center. Dr. Shneider has clinical expertise in the diagnosis and care of patients with ALS and related motor neuron diseases. 

Academic Titles

  • Associate Professor of Neurology

Administrative Positions

  • Director, Eleanor and Lou Gehrig ALS Center
  • Director, ALSA/ALS Clinic

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
710 West 168th Street
New York, New York 10032
Phone:
(212) 305-1319
Primary

Research

Models and Mechanisms of Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the motor system that primarily involves spinal and bulbar motor neurons and their descending, corticospinal inputs.  ALS is genetically complex, and can be caused by mutations in a large and growing number of genes encoding proteins of diverse function.  Using mouse genetics, we have generated and characterized several animal and cellular models of ALS to explore molecular mechanisms of disease and to elucidate pathways of motor neuron degeneration that may be targets for drug discovery.  Work in the lab focuses on:

• the role of mutant FUS, TDP-43 and related ALS-associated RNA binding proteins in motor neuron degeneration.  In particular, we are interested in the propensity of these proteins to form abnormal ribonucleoprotein assemblies that are selectively toxic to motor neurons.  We use a combination of molecular, biochemical and computational methods to explore mechanisms of disease onset and progression in ALS

• molecular mechanisms of neurodegeneration caused by a hexanucleotide expansion in the gene C9orf72, the most common cause of familial ALS and frontotemporal dementia (FTD)

• the role of ALS mutant astrocytes and oligodendrocytes in the pathogenesis of ALS

• the role of motor neuron excitability and synaptic excitation in motor neuron dysfunction and degeneration

• genetic studies in novel animal and cellular models of ALS to validate promising pathways of disease; in vitro studies to screen small molecules and identify candidate therapeutics for ALS

In addition, our group is interested and involved in patient-based basic, translational and clinical research that focuses on:

• whole genome sequencing of ALS patients to elucidate novel disease pathways and potential targets

• phenotype-genotype correlation studies

• the generation and characterization of human, cellular models of ALS based on induced pluripotent stem cell (iPS) lines from clinically well-characterized patients

• early phase drug discovery

Research Interests

  • Neural Degeneration and Repair
  • Models of Neurological Disorders
  • Amyotrophic Lateral Sclerosis
  • Neurobiology of Disease
  • Genetic Basis of Neurological Disease

Grants

SMN DYSFUNCTION IN FUS-DEPENDENT ALS (Federal Gov)

Aug 15 2016 - Jul 31 2018

FUS GAIN-OF-FUNCTION MECHANISMS IN ANIMAL AND CELLULAR MODELS OF ALS (Federal Gov)

Sep 1 2011 - Jul 31 2018

THE ROLE OF PLD1 AND PLD2 IN NEURODEGENERATIVE PATHWAYS COMMON TO ALS AND AD (Private)

Mar 7 2016 - Mar 6 2018

GENE THERAPEUTIC MODULATION OF NMD FOR TEATMENT OF ALS (Private)

Jan 1 2017 - Dec 31 2017

EXPLORING THE MECHANISMS OF MUTANT FUS- MEDIATED MOTOR NEURON DEGENERATION IN ALS: AN IN VITRO APPROACH (Private)

Dec 31 2016 - Dec 31 2017

TARGET ALS POSTMORTEM CORE (Private)

Jul 1 2016 - Jun 30 2017

IDENTIFICATION OF LIPID BIOMARKERS FOR AMYOTROPHIC LATERAL SCLEROSIS (Private)

Mar 15 2015 - Feb 14 2017

ALSA PROPOSAL FOR ADDING BIOFLUIDS TO TARGET ALS POSTMORTEM TISSUE CORE (Private)

Jan 1 2016 - Dec 31 2016

EXPLORING THE MECHANISMS OF MUTANT FUS-MEDIATD MOTO NEURON DEGENERATION IN ALS: AN IN VITRO APPROACH APPROACH (Private)

Dec 31 2015 - Dec 31 2016

OPTINEURIN LOSS OF FUNCTION AS A MECHANISM OF MOTOR NEURON DEGENERATION IN ALS (Private)

May 1 2014 - May 1 2016

CELL AUTONOMOUS AND NON-CELL AUTONOMOUS MECHANISMS OF RNA-BINDING PROTEIN-MEDIATED MOTOR NEURON DEGENERATION IN ALS: AN IN VITRO APPROACH (Private)

Dec 31 2013 - Dec 31 2015

P2 ALS PHASE TWO: TESTING TARGETS (A COLLABORATIVE, GOAL-DRIVEN NETWORK FOR TRANSLATIONAL ALS RESEARCH) (Private)

Feb 1 2013 - Dec 31 2015

SHARED RESOURCES SUPPORT FOR SCI RESEARCH AT THE COLUMBIA MOTOR NEURON CENTER (NY State Gov)

Dec 1 2014 - Aug 31 2015

SHARED RESOURCES SUPPORT FOR SCI RESEARCH AT THE COLUMBIA MOTOR NEURON CENTER (NY State Gov)

Oct 1 2014 - Feb 28 2015

ALS GENOME SEQUENCING PROJECT (Private)

Jun 18 2012 - Jun 17 2014

P2 ALS INITIATIVE (Private)

Jan 1 2010 - Dec 31 2013

MOLECULAR PROFILING OF GAMMA MOTOR NEURON DEVELOPMENT (Federal Gov)

Sep 1 2010 - Jun 30 2013

Selected Publications

Selected publications:

  • Aarti Sharma, Alexander K. Lyashchenko, Lei Lu, Sara Ebrahimi Nasrabady, Margot Elmaleh, Monica Mendelsohn, Adriana Nemes, Juan Carlos Tapia, George Z. Mentis, Neil A. Shneider. ALS-Associated Mutant FUS Induces Selective Motor Neuron Degeneration through Toxic Gain of Function.  Nature Communications. 2016 Feb 4;7:10465. doi: 10.1038/ncomms10465. PubMed PMID: 26842965.
  • Valerie C. Siembab, Laura Gomez-Perez, Travis M. Rotterman, Neil A. Shneider, Francisco J. Alvarez (2015).  Role of Primary Afferents in the Developmental Regulation of Motor Axon Synapse Numbers on Renshaw Cells.  Journal of Comparative Neurology. 2015 Dec 11.
  • Tetsuro Murakami, Seema Qamar, Julie Qiaojin Lin, Gabriele S. Kaminski Schierle, Eric Rees, Akinori Miyashita, Ana R. Costa, Roger B. Dodd,  Fiona T.S. Chan, Claire H. Michel, Deborah Kronenberg-Versteeg, Yi Li, Seung-Pil Yang, William Meadows, Rodylyn Rose Ferry, Liang Dong, Gian Gaetano Tartaglia, Giorgio Favrin, Wen-Lang Lin, Dennis W. Dickson, Mei Zhen, Gerold Schmitt-Ulms, Paul E. Fraser, Neil A. Shneider, Christine Holt, Michele Vendruscolo, Clemens F. Kaminski, Peter St George-Hyslop (2015).  FUS mutations induce formation of irreversible hydrogel-like assemblies that impair RNP granule function.  Neuron 2015 Oct 28. pii: S0896-6273(15)00924-1.
  • Elizabeth T. Cirulli, Brittany N. Lasseigne, Slavé Petrovski, Peter C. Sapp, Patrick A. Dion, Claire S. Leblond, Julien Couthouis, Yi-Fan Lu, Quanli Wang, Brian J. Krueger, Zhong Ren, Jonathan Keebler, Yujun Han, Shawn E. Levy, Braden E. Boone, Jack R. Wimbish, Lindsay L. Waite, Angela L. Jones, John P. Carulli, Aaron G. Day-Williams, John F. Staropoli, Winnie W. Xin, Alessandra Chesi, Alya R. Raphael, Diane McKenna-Yasek, Janet Cady, J.M.B. Vianney de Jong, Kevin P. Kenna, Bradley N. Smith, Simon Topp, Jack Miller, Athina Gkazi, FALS Sequencing Consortium, Ammar Al-Chalabi, Leonard H. van den Berg, Jan Veldink, Vincenzo Silani, Nicola Ticozzi, Christopher E. Shaw, Robert H. Baloh, Stanley Appel, Ericka Simpson, Clotilde Lagier-Tourenne, Stefan M. Pulst, Summer Gibson, John Q. Trojanowski, Lauren Elman, Leo McCluskey, Murray Grossman, Neil A. Shneider, Wendy K. Chung, John M. Ravits, Jonathan D. Glass, Katherine B. Sims, Vivianna M. Van Deerlin, Tom Maniatis, Sebastian D. Hayes, Alban Ordureau, Sharan Swarup, John Landers, Frank Baas, Andrew S. Allen, Richard S. Bedlack, J. Wade Harper, Aaron D. Gitler, Guy A. Rouleau, Robert Brown, Matthew B. Harms, Gregory M. Cooper, Tim Harris, Richard M. Myers, David B. Goldstein (2015).   Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015 Mar 27;347(6229):1436-41.
  • Xinmei Wen, Wenzhi Tan, Thomas Westergard, Karthik Krishnamurthy, Shashirekha S. Markandaiah,Yingxiao Shi, Shaoyu Lin, Neil A. Shneider, John Monaghan, Udai B. Pandey, Piera Pasinelli,Justin K. Ichida, Davide Trotti (2014). Antisense Proline-Arginine RAN Dipeptides Linked to C9ORF72-ALS/FTD Form Toxic Nuclear Aggregates that Initiate In Vitro and In Vivo Neuronal Death.  Neuron 84 (6), 17 December 2014, 1213–1225.